For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 66,507 | -27,981* | 58,989 | 54,710 |
| General and administrative | 22,872 | 15,746* | 14,798 | 15,741 |
| Other license income | - | 25,000* | - | - |
| Gains on sale of non-financial assets | - | 2,562* | - | - |
| Total operating expenses | 89,379 | -39,798 | 73,787 | 70,451 |
| Gain from operations | -89,379 | 39,798* | -73,787 | -70,451 |
| Interest and other income, net | 13,601 | 10,205* | 8,183 | 8,929 |
| Gain before provision for income taxes | -75,778 | 50,003* | -65,604 | -61,522 |
| Provision for income taxes | 190 | 145* | 108 | 139 |
| Net gain attributable to ordinary shareholders | -75,968 | 49,858* | -65,712 | -61,661 |
| Unrealized loss on investments, net | -3,249 | 125 | 463 | -453 |
| Total other comprehensive loss | -3,249 | 125* | 463 | -453 |
| Comprehensive gain | -79,217 | 49,983 | -65,249 | -62,114 |
| Basic EPS | -0.35 | 0.271 | -0.37 | -0.36 |
| Diluted EPS | -0.35 | 0.278 | -0.37 | - |
| Basic Average Shares | 217,326,000 | 184,672,000 | 175,469,000 | 172,647,000 |
| Diluted Average Shares | 217,326,000 | 179,723,000 | 175,469,000 | - |
Structure Therapeutics Inc. (GPCR)
Structure Therapeutics Inc. (GPCR)